The ITAT ruled favorably on multiple issues for the appellant....

The ITAT ruled favorably on multiple issues for the appellant. ESOP expenses were deemed allowable under section 37(1), consistent with treatment in prior years. Expenditure on clinical trials was held eligible for weighted deduction under section 35(2AB), though limited to amounts certified in Form 3CL. The Tribunal directed deletion of additions to book profit under section 115JB related to section 14A disallowances. CSR expenses were held eligible for section 80G deduction subject to verification of prescribed conditions. Several matters were remanded to the AO, including verification of business promotion expenses, section 35DD deduction claims, inventory write-down values, and TDS credit for the merged entity Strides Emerging Market Limited.